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lial transformation towards an amoeboid morphology is
inhibited by rAv17. Av-cystatin caused a time-dependent 
downregulation of proinflammatory cytokines, iNOS and 
COX-2 mRNA expression, respectively. This was paralleled by 
an upregulated expression of IL-10 in resting as well as in 
LPS-stimulated microglia. Av-cystatin reduced the release of 
NO and TNF-α in the culture supernatant. Immunocyto-
chemical staining demonstrated an attenuated transloca-
tion of NF-ĸB by Av-cystatin in response to LPS. In addition, 
Western blot analysis revealed a rAv17-dependent reduc-
tion of the LPS-induced ERK1/2-pathway activation.  Conclu-
sion: The parasite-derived secretion product Av-cystatin in-
hibits proinflammatory mechanisms of LPS-induced microg-
lia with IL-10, a potential key mediator. 
 © 2016 S. Karger AG, Basel 
 Introduction 
 Several investigators focus on the pathophysiology of 
neurodegenerative diseases (ND). In this context, a dys-
regulated response of the neuroimmune system – termed 
neuroinflammation – is a main contributor to the chron-
ic progression of ND. Neuroinflammation is mainly ex-
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 Abstract 
 Objective: The aim of this study was to examine whether the 
natural protease inhibitor Av-cystatin (rAv17) of the parasit-
ic nematode  Acanthocheilonema viteae exerts anti-inflam-
matory effects in an in vitro model of lipopolysaccharide 
(LPS)-activated microglia.  Methods: Primary microglia were 
harvested from the brains of 2-day-old Wistar rats and cul-
tured with or without rAv17 (250 n M ). After 6 and 24 h the 
release of nitric oxide (Griess reagent) and TNF-α (ELISA) was 
measured in the supernatant. Real-time PCR was performed 
after 2, 6 and 24 h of culture to measure the mRNA expres-
sion of IL-1β, IL-6, TNF-α, COX-2, iNOS and IL-10. To address 
the involved signaling pathways, nuclear NF-ĸB transloca-
tion was visualized by immunocytochemistry. Morphologi-
cal changes of microglia were analyzed by Coomassie blue 
staining. Differences between groups were calculated using 
one-way ANOVA with Bonferroni’s post hoc test.  Results: 
Morphological analysis indicated that LPS-induced microg-
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erted by activated microglia faced with protracted activat-
ing stimuli. Subsequently, such activated microglia ac-
quire maladaptive functions and a proinflammatory 
phenotype. This makes microglial activation and adap-
tion an interesting target in the study of potential immu-
nomodulators.
 However, the process of microglia activation seems to 
be more complex. Recent studies have investigated the 
plasticity of microglial cells and detailed gene expression 
analyses revealed that monomorphic-activated microglia 
might accomplish entire distinct functions. Like macro-
phages, microglial cells seem to be functionally polarized 
into different phenotypes, meaning that different activa-
tion states are known  [1, 2] . 
 Classical activation characterizes a phenotype that 
seems to dominate under neurodegenerative conditions. 
This phenotype is characterized by the production of pro-
inflammatory cytokines (e.g. IL-1β, IL-6, TNF-α), nitric 
oxide (NO) and other reactive oxygen species  [3] . Ac-
cordingly, enzymes such as iNOS (inducible NO-syn-
thase) and COX-2 (cyclooxygenase 2) have also been as-
sociated with ND  [3–6] . Such activated microglial cells 
promote neurodegeneration in experimental models in 
vitro and in vivo  [7–9] .
 The second state is alternative activation, by which mi-
croglia take on an anti-inflammatory phenotype. Differ-
ent markers have been described to characterize this phe-
notype. Another way to classify the function and pheno-
type of cells is based on the cytokines that induce them. 
According to this concept, immunomodulatory agents 
could be separated into those leading to a proinflamma-
tory or an anti-inflammatory phenotype  [1] . However, 
there is no gold standard set of markers that finally dis-
criminates between these phenotypes.
 Parasitic worms have evolved highly efficient media-
tors to protect themselves and the host tissues from this 
immune-mediated damage  [10] . Here we use a member of 
the filarial cystatin family, recombinant Av-cystatin 
(rAv17), a 17-kDa protein of the parasitic nematode  Acan-
thocheilonema viteae  (Av). Cystatins belong to a family of 
cysteine protease inhibitors and represent important reg-
ulators of highly efficient proteolytic processes, such as the 
processing of protein precursors or antigen processing 
 [11] . rAv17 is secreted, which suggests that it might have 
important functions in the host-parasite interplay. Cys-
tatins produced by Av are protective in allergic airway pa-
thology and colitis  [12] . It was shown to affect monocytes 
and macrophages, which subsequently achieved a regula-
tory type-II-activated phenotype with anti-inflammatory 
properties  [13, 14] . One of the key cytokines inducing an 
anti-inflammatory phenotype is IL-10. IL-10 has exten-
sive immune-regulatory properties in controlling and re-
ducing an excessive immune response during infection or 
autoimmunity. This is mainly due to the suppressed pro-
duction of proinflammatory cytokines in macrophages. In 
the context of cellular phenotypes, T helper (Th) cells are 
known to be functionally polarized into different T-cell 
phenotypes and IL-10 is an important regulator towards 
Th2-cells. Here, using a cell culture model of primary rat 
microglia, we demonstrate that the application of rAv17 
modulates the classical activation state of lipopolysaccha-
ride (LPS)-stimulated microglia in vitro, thereby reducing 
the expression of proinflammatory cytokines and elevat-
ing the expression of IL-10.
 Materials and Methods 
 Microglia Cell Culture 
 Wistar rats were used for all experiments and were bred and 
kept under constant conditions (12/12 h light/dark cycle) in the 
animal house of the University of Kiel. Primary cultures were pre-
pared from rostral mesencephali and cerebral hemispheres of 
2-day-old rats. The meninges, hippocampi and choroid plexus 
were removed from the brains, and the cortices and mesencephali 
were minced and mechanically dissociated by trituration using 
fire-polished Pasteur pipettes, followed by enzymatic digestion 
with trypsin (from bovine pancreas, type III; Invitrogen) and
DNAse I (Roche). Suspended mixed brain cells were plated in a 
culture flask (diameter 100 mm; Sarstedt) in 10 ml of growth me-
dium (DMEM; Invitrogen) supplemented with 10% fetal bovine 
serum (Invitrogen),  L -glutamine (Sigma), 1% penicillin (10,000 U/
ml; PAA) and streptomycin (10 mg/ml; PAA). All cells were cul-
tured in a humidified atmosphere enriched with 5% CO 2 . Free-
floating microglial cells were collected from the medium of pri-
mary cell cultures from neonatal rat cerebral cortices after 10 days, 
as described previously  [15] . Prior to replanting the microglial cells 
for the different experiments, the cell number and viability was 
estimated by trypan-blue exclusion. Viable cells were seeded onto 
12-well culture plates [100,000 cells/well for Coomassie and im-
munocytochemical staining and 1,000,000 cells/well for quantita-
tive real-time PCR (q-PCR), NO measurement, ELISA and West-
ern blot] and grown for 24 h at 37  °  C in a humidified atmosphere 
enriched with 5% CO 2 . For the observation of morphological 
changes in cell shape, the cells were fixed with 2% glutaraldehyde 
in phosphate-buffered saline (PBS) after 24 h of stimulation and 
stained with Coomassie blue dye (Bio-Rad). Cell analysis was per-
formed from three independent experiments using an Axiophot 
microscope (Zeiss, Wetzlar, Germany) with a 40× objective and 
10× eye piece. The mean value of pseudopodia from each section 
was calculated based on a total of 30 cells for each experimental 
subgroup. The quantitative size objectification was performed for 
the same cells using the computer software ImageJ.
 Treatment of Cells 
 Recombinant and LPS-free rAv17 was produced according to 
Schnoeller et al.  [12] . For the induction of microglial activation, 
 LPS-Induced Proinflammatory Phenotype 
Modulation of Microglia 
Neuroimmunomodulation 2016;23:109–121
DOI: 10.1159/000444756
111
LPS (10 ng/ml, from  Salmonella typhimurium ; Sigma), a bacterial 
endotoxin and generally accepted inducer of proinflammatory 
properties  [16, 17] , was added to the positive control groups. The 
experimental groups were incubated with the recombinant immu-
nomodulatory protein rAv17 (low dose, 250 n M ; high dose, 500 
n M ), dissolved in PBS (Gibco), or with LPS and rAv17. The control 
groups remained untreated. As the end points of stimulation we 
chose 24 h for morphological analyses, 6 and 24 h for nitrite mea-
surements, 2, 6 and 24 h for q-PCR, 6 and 24 h for TNF-α-ELISA, 
15 min for Western blot analyses and 60 min for NF-κB staining. 
For stimulating experiments the experimental groups were incu-
bated with LPS and rAv17 simultaneously, except from Western 
blot experiments where microglia were preincubated with rAv17 
30 min before the LPS was added. 
 Measurement of Nitrite Production 
 The nitrite concentration in the culture supernatant was used 
as a measure of NO production. After 6 and 24 h of incubation, 
the generation of NO in the cell culture supernatants was deter-
mined by measuring nitrite accumulation in the medium using 
Griess reagent (0.5% sulfanilamide and 0.05%  N -(1-naphthyl)-
ethylenediamine dihydrochloride in 0.25% H 3 PO 4 ; Sigma). One 
hundred microliters of culture supernatant and 100 μl of Griess 
reagent were mixed and incubated for 5 min. The absorption was 
estimated in an automated plate reader (SLT reader 340 ATTC) 
at 540 nm. For both concentrations of rAv17 the results were ob-
tained from three independent experiments of identically treated 
cells.
 Quantitative Real-Time PCR 
 After 2, 6 and 24 h of incubation the cell supernatant was dis-
carded and the microglia were washed three times with PBS (4  °  C). 
RNA was isolated with the QIAzol reagent and contaminating 
DNA was digested by DNase (Promega, Mannheim, Germany). In 
the next step the RNA was transcribed in cDNA using random 
hexamer primer (Fermentas) and reverse transcriptase (Revert-
Aid TM H Minus M-muLV; Fermentas). Ten nanograms of cDNA 
were used for q-PCR amplification. q-PCR was performed in two 
replicates of each sample using TaqMan ® primer probes (assays-
on-demand; Applied Biosystems) on an ABI Prism 7000 thermo-
cycler using assays-on-demand and chemistries as recommended 
by the manufacturer (all Applied Biosystems). The q-PCR signal 
of the target transcript in the treatment groups was related to that 
of the control by relative quantification. The 2 –ΔΔC T method was 
used to analyze the relative changes in gene expression. The house-
keeping gene 18s rRNA was used as an internal control to normal-
ize the q-PCR for the amount of RNA added to the reverse tran-
scription reactions. Data are expressed as the percent change of 
gene expression relative to LPS-stimulated controls (100%). Taq-
Man assays had the following identification numbers: 18s: Hs 
99999901, iNOS: Rn 00561646, TNFα: Rn 99999017, IL-6: Rn 
00561420, IL-1β: Rn 00580432, IL-10: Rn00563409, COX-2: 
Rn00568225.
 Enzyme Immune Assay of TNF-α 
 TNF-α protein in microglia culture supernatants was measured 
by solid-phase sandwich enzyme-linked immunosorbent assay 
(ELISA), using a monoclonal capture antibody specific for TNF-α 
protein (all antibodies from BD Bioscience, Franklin Lakes, N.J., 
USA). TNF-α ELISA was performed using the BD OptEIA TNF-
ELISA-Kit (all from BD Bioscience). After 6 and 24 h of incuba-
tion, collected culture medium was harvested and treated accord-
ing to the instructions of the manufacturer. The wells of a 96-mi-
crotiter plate were coated with the TNF-α capture antibody 
overnight at 4  °  C. Wells were blocked with assay diluent and incu-
bated with 100 ml of the culture supernatant at room temperature 
for 2 h. Antibody binding was detected via biotin-conjugated de-
tection antibody and the manufacturer’s substrate reagent set. The 
concentration of TNF-α was calculated according to the equation 
obtained from the standard curve plot using the TNF-α standard 
solution provided with the ELISA kit. 
 Immunocytochemical NF-ĸB Staining 
 To assess the activity of the NF-ĸB pathway, we visualized the 
translocation of the p65 subunit into the nucleus. Isolated mi-
croglia were cultured onto coverslips for 24 h and fixed with 
Zamboni’s reagent (4% paraformaldehyde and 0.2% picric acid, 
dissolved in PBS) for 1 h at room temperature. Afterwards, the 
cells were stained with antibodies against NF-ĸB p65 (Santa Cruz 
Biotechnology) for 60 min at room temperature and in a second 
step with fluorescent anti-rabbit antibodies (Invitrogen) for 45 
min at room temperature. The immunoreaction was visualized 
by fluorescence microscopy (Zeiss Axiovert, Carl Zeiss Micros-
copy). The quantitative objectification from each section was cal-
culated based on a total of 10 cells for each experimental sub-
group. The objectification was done via densitometric analysis 
using ImageJ computer software and the results for cells treated 
with rAv17 were compared to those stimulated solely with LPS 
(100%).
 Western Blot Analysis  
 For Western blot analysis microglial cells were pretreated 
with rAv17 (250 n M ) for 30 min before stimulation with 10 ng/
ml of LPS. After 15 min of incubation the cell supernatant was 
discarded and the microglia were washed twice with PBS (4   °   C), 
harvested in PBS by scraping, and centrifuged. Cellular protein 
was isolated from the cells using 100 μl of lysis buffer (199 m M 
NaCl, 50 m M TRIS, 5 m M EDTA, 1% Triton X-100, 2 m M sodium 
vanadate, 2.5 m M sodium pyrophosphate, 1 m M β-glycerol phos-
phate, 1 m M phenylmethylsulfonyl fluoride). Protein aliquots (5 
μg) were sorted by 12.5% SDS-PAGE and Western blotted with 
phospho-specific antibodies against phosphorylated ERK 
(pERK1/2; Cell Signaling Technology, Danvers, Mass., USA) 
overnight at 4   °   C according to the manufacturer’s protocol. An-
tibody binding was detected via enhanced chemiluminescence 
(Amersham Pharmacia Biotech, Essex, UK). The quantitative ob-
jectification was done via densitometric analysis using computer 
software PC-BAS 2.0.
 Statistical Analysis 
 All experiments were performed at least three times and values 
represent the mean ± standard error of the mean (SEM). Statistical 
analysis of the data was accomplished using a one-way ANOVA 
indicating significant differences, and comparisons among the 
various experimental groups was made using Bonferroni’s post 
hoc test. Student’s t test was used when two groups were consid-
ered. Differences were considered significant with p  ≤ 0.05. Quan-
titative data are presented as the mean ± SEM and confidence in-
tervals (CI; lower limit, upper limit); n represents the number of 
independent experiments. 
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 Results 
 Morphological Alterations of Microglia Cells by rAv17 
 To examine whether rAv17 alters the morphology of 
microglia in vitro, we exposed cells to the protein in the 
absence and presence of LPS for 24 h and measured the 
number of pseudopodia and the cell size (cell area). Un-
treated cells ( fig. 1 a) developed the typical ramified mor-
phology of resting microglia  [18] with a small cell size (187 
± 11.4 μm 2 , 95% CI 163–211) and numerous pseudopodia 
(3.1 ± 0.23; 95% CI 2.62–3.57). In comparison, LPS-stim-
ulated cells ( fig. 1 b) presented the characteristic amoeboid 
phenotype of activated microglia with significantly larger 
soma (811 ± 51.7 μm 2 ; 95% CI 702–919; p < 0.001) and a 
reduced number of pseudopodia (0.8 ± 0.17; 95% CI 0.44–
1.16; p < 0.001). The addition of rAv17 alone did not result 
in an LPS-like phenotype transformation ( fig. 1 c), but was 
very similar to resting microglia. There was neither a sig-
nificant reduction of pseudopodia (3.15 ± 0.42; 95% CI 
2.24–4.07; p > 0.05) nor an increased cell size (205 ± 19.7 
μm 2 ; 95% CI 162–248; p > 0.05). The shape of the microg-
lia simultaneously exposed to LPS and rAv17 resembled a 
mixed phenotype ( fig.  1 d); nevertheless, they presented 
significantly more pseudopodia (1.87 ± 0.26; 95% CI 1.32–
2.42; p < 0.05) and a smaller soma (293 ± 30.4 μm 2 ; 95% 
CI 227–358; p < 0.001) compared to LPS-treated cells. 
This indicates that microglial transformation towards an 
amoeboid morphology is partly inhibited by rAv17.
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 Fig. 1.  a–e LPS-induced transformation of 
ramified microglia is blocked by rAv17. 
Representative photomicrographs of in vi-
tro-cultivated microglia.  a Resting microg-
lia cells (control).  b LPS (10 ng/ml)-stimu-
lated amoeboid microglia (positive con-
trol).  c The addition of rAv17 (250 n M ) did 
not alter the morphology of resting mi-
croglia.  d rAv17 (250 n M ) inhibited the LPS 
(10 ng/ml)-induced amoeboid microglia 
transformation. Scale bar = 20 μm.  e This 
interpretation was confirmed by the quan-
tification of the cell area (ca; μm) and 
counting the number of pseudopodia (p). 
The data were assessed from 30 cells per 
experimental subgroup of three indepen-
dent experiments. Letters (a, b, c, A, B) in-
dicate clusters of experimental groups 
which are significantly different from each 
other (p < 0.05). All data are the mean ± 
SEM (95% CI values are given in the text). 
Cells were cultivated upon cover glasses 
and stimulated with the indicated reagents 
for 24 h. After fixation with 2.5% glutaral-
dehyde cells were stained with Coomassie 
blue dye. 
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 rAv17 Reduces LPS-Induced Expression of iNOS 
mRNA and NO Synthesis in Microglia 
 LPS induced the expression of iNOS and mediated the 
production of large amounts of NO in microglia  [19, 20] . 
To test whether rAv17 reduces the amount of NO radi-
cals, we exposed microglia to the protein in the absence 
or presence of LPS. Sole rAv17 (250 n M ) did not alter the 
levels of iNOS mRNA expression (6 h: 3.80 ± 1.1%; 95% 
CI 0.22–7.23; 24 h: 0.67 ± 0.33%; 95% CI –0.77–2.11) and 
NO release (6 h: 33.26 ± 3.7%; 95% CI 21.57–44.59; 24 h: 
7.58 ± 3.2%; 95% CI –2.44 to 17.61) at both time points. 
In contrast, LPS significantly increased both parameters 
at 6 and 24 h (each 100%). Simultaneous exposure to LPS 
and rAv17 (250 n M ) significantly reduced the level of 
LPS-induced iNOS mRNA at 6 h (83.51 ± 6.46%; 95% CI 
62.94–104.1; p < 0.05) and 24 h (70.67 ± 10.35%; 95% CI 
26.14–115.20; p < 0.05;  fig. 2 a, b). Additionally, this was 
accompanied by a reduction of NO at 6 h (trend: 92.88 ± 
0
a
a a
b b
a a a
a
aa
b
c b, c
b
c b, c
Co
ntr
ol LP
S
LP
S +
 rA
v1
7 (
25
0 n
M)
Co
ntr
ol
rA
v1
7 (
25
0 n
M)
rA
v1
7 (
50
0 n
M) LP
S
LP
S +
 rA
v1
7 (
25
0 n
M)
LP
S +
 rA
v1
7 (
50
0 n
M)
rA
v1
7 (
25
0 n
M)
Co
ntr
ol LP
S
LP
S +
 rA
v1
7 (
25
0 n
M)
rA
v1
7 (
25
0 n
M)
a
b
c
50
100
n-
fo
ld
 m
RN
A 
ex
pr
es
si
on
 o
f i
N
O
S
(%
 o
f L
PS
-t
re
at
ed
 c
el
ls
)
150
Co
ntr
ol
rA
v1
7 (
25
0 n
M)
rA
v1
7 (
50
0 n
M) LP
S
LP
S +
 rA
v1
7 (
25
0 n
M)
LP
S +
 rA
v1
7 (
50
0 n
M)
0
50
100
N
O
 re
le
as
e
(%
 o
f L
PS
-t
re
at
ed
 c
el
ls
)
150
0
50
100
N
O
 re
le
as
e
(%
 o
f L
PS
-t
re
at
ed
 c
el
ls
)
150
0
50
100
n-
fo
ld
 m
RN
A 
ex
pr
es
si
on
 o
f i
N
O
S
(%
 o
f L
PS
-t
re
at
ed
 c
el
ls
)
150
a b
c d
 Fig. 2. The immunomodulator rAv17 reduces the expression of 
iNOS mRNA ( a ,  b ) and the NO synthesis ( c ,  d ) in cultivated mi-
croglia. Cells were stimulated for 6 ( a ,  c ) and 24 h ( b ,  d ) with rAv17 
(250 n M at 6 h, 250 and 500 n M at 24 h), LPS (10 ng/ml) and simul-
taneously with rAv17 + LPS, respectively. mRNA expression was 
analyzed using TaqMan q-PCR and results for cells treated with 
rAv17 were compared to those stimulated solely with LPS. 18s 
RNA (a housekeeping gene) was used as the internal control. The 
data were assessed from at least 3 independent experiments, each 
run in duplicate. Letters (a, b, c) indicate clusters of experimental 
groups which are significantly different from each other (p < 0.05; 
detailed p values are given in the text). All data are the mean ± SEM 
(95% CI values are given in the text).  
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2.25%; 95% CI 85.72–100.0; not significant) and signifi-
cantly at 24 h (86.34 ± 2.01%; 95% CI 79.73–92.95; p < 
0.01;  fig. 2 c, d). Thus, the reduced production of NO rad-
icals seems to be mediated in part by inhibited iNOS ex-
pression in LPS-stimulated microglia. Experiments with 
a higher molecular dosage of rAv17 (500 n M ) showed a 
comparable effect with respect to LPS without reaching 
significance [LPS + rAv17 (500 n M ): iNOS, 24 h: 68.2 ± 
16.3%; 95% CI 16.3–120.0; p > 0.05; NO, 24 h: 88.3 ± 
2.71%; 95% CI 76.68–99.98; p > 0.05].
 rAv17 Inhibits Proinflammatory Cytokine
mRNA Expression and TNF-α Release by
Microglia in a Time-Dependent Manner 
 LPS-activated microglia produce an array of neuro-
toxic proinflammatory cytokines like IL-1β, IL-6 and 
TNF-α  [21] . To study the capacity of rAv17 to modulate 
the production of these proinflammatory cytokines, we 
exposed microglia to the protein in the absence or pres-
ence of LPS and analyzed the mRNA expression of IL-1β, 
IL-6 and TNF-α by q-PCR. rAv17 (250 n M ) alone signifi-
cantly increased the level of IL-1β (30.0 ± 9.37%; 95% CI 
5.9–54.1) and TNF-α mRNA (33.5 ± 8.65%; 95% CI 5.99–
61.01) at 6 h (both p < 0.05) but not at 24 h (IL-1β: 8.67 ± 
1.20%; 95% CI 3.49–13.84; TNF-α: 41.67 ± 4.7%; 95% CI 
21.43–61.9;  fig. 3 a, b, e, f), whereas it did not alter the lev-
els of IL-6 mRNA (6 h: 7.0 ± 3.51%; 95% CI –8.11–22.1; 
24 h: 1.33 ± 0.33%; 95% CI –0.10 to 2.77;  fig. 3 b–d). In 
contrast, LPS induced a substantial rise of all measured 
cytokine mRNAs (100%). Simultaneous exposure of mi-
croglia to rAv17 and LPS revealed a time-dependent ef-
fect of rAv17 on LPS-induced cytokine expression. After 
6 h the effect of rAv17 (250 n M ) modulation was hetero-
geneous. It significantly (p < 0.05) increased the level of 
IL-6 mRNA (130.4 ± 10.8%; 95% CI 83.64–177.2) while 
having no effects on the expression levels of IL-1β and 
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 Fig. 4.  a ,  b rAv17 inhibits proinflammatory TNF-α release by mi-
croglia in a time-dependent manner. Cells were stimulated for 6 
( a ) and 24 h ( b ) with rAv17 (250 n M ), LPS (10 ng/ml) and simul-
taneously with rAv17 + LPS, respectively. TNF-α protein release 
was measured by ELISA using the BD-OptEIA TNF-ELISA kit and 
results for cells treated with rAv17 were compared to those stimu-
lated solely with LPS. All data were assessed from at least 3 inde-
pendent experiments. Letters (a, b) indicate clusters of experimen-
tal groups which are significantly different from each other (p < 
0.05; detailed p values are given in the text). All data are the mean 
± SEM (95% CI values are given in the text).  
 Fig. 3.  a–f rAv17 inhibits proinflammatory cytokine mRNA ex-
pression by microglia in a time-dependent manner. Cells were 
stimulated for 6 ( a ,  c ,  e ) and 24 h ( b ,  d ,  f ) with rAv17 (250 n M at
6 h, 250 and 500 n M at 24 h), LPS (10 ng/ml) and simultaneously 
with rAv17 + LPS, respectively. The expression of mRNA was an-
alyzed using TaqMan q-PCR and results for cells treated with 
rAv17 were compared to those stimulated solely with LPS. 18s 
RNA (a housekeeping gene) was used as the internal control. All 
data were assessed from at least 3 independent experiments, each 
run in duplicate. Letters (a, b, c) indicate clusters of experimental 
groups which are significantly different from each other (p < 0.05; 
detailed p values are given in the text). All data are the mean ± SEM 
(95% CI values are given in the text). 
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TNF-α mRNAs. In contrast, rAv17 (250 n M ) significant-
ly reduced the mRNA-levels of all the measured cytokines 
after 24 h ( fig. 3 a–f): IL-1β: 66.0 ± 9.71%; 95% CI 24.21–
107.8; p < 0.01; IL-6: 80.33 ± 5.49%; 95% CI 56.72–103.9; 
p < 0.01; TNF-α: 61.67 ± 7.97; 95% CI 27.4–95.94; p < 
0.05). Application of rAv17 in a higher molecular dose 
(500 n M ) reduced the mRNA expression of all investi-
gated proinflammatory cytokines and showed distinct 
differences compared to low-dose rAv17 + LPS after 24 h 
[LPS vs. LPS + rAv17 (250 n M ): IL-1β, 70.7.0 ± 7.04%; 
95% CI 48.3–93.1; p < 0.01; IL-6, 60.8 ± 15.8%; 95% CI 
10.6–111.0; p < 0.05; TNF-α, 78.4 ± 5.29; 95% CI 55.7–
101.0; p > 0.05]. There were no statistical significant dif-
ferences when both rAv17 doses were compared. The re-
duced level of TNF-α mRNA is in line with decreased 
protein levels of TNF-α measured by ELISA of cell culture 
supernatant. Here, rAv17 (250 n M ) had no effect on the 
LPS-induced TNF-α release after 6 h (100.1 ± 1.28%; 95% 
CI 96.01–104.2), but significantly (p < 0.01) reduced its 
release after 24 h (88.02 ± 3.80%; 95% CI 75.92–100.1; 
 fig. 4 a, b). Thus, no immediate effect of rAv17 could be 
seen after 6 h, but it significantly reduced all measured 
proinflammatory cytokine mRNAs and the secreted 
TNF-α at 24 h. 
 rAv17 Reduces the mRNA Expression of COX-2
in a Time-Dependent Manner 
 The proinflammatory enzyme COX-2 is associated 
with microglia activation by the production of the proin-
flammatory protein PGE2 (prostaglandin E2)  [4] . Thus, 
we measured the effect of rAv17 (250 n M ) on the LPS-
induced COX-2 expression via q-PCR as a marker of mi-
croglia activation ( fig. 5 a, b). rAv17 alone had no signifi-
cant effect (6 h: 20.4 ± 6.59%; 95% CI 2.11–38.68; 24 h: 
3.00 ± 0.01; 95% CI 3.0–2.99), whereas LPS strongly up-
regulated COX-2 mRNA production at 6 and 24 h (both 
100%). The concomitant exposure of microglia to rAv17 
and LPS showed an increase of COX-2 mRNA expression 
after 6 h (120.2 ± 6.78%; 95% CI 101.4–139.0; p < 0.05), 
whereas a significant (p < 0.05) reduction was observed 
after 24 h (67.50 ± 11.61; 95% CI 30.56–104.4; p < 0.05). 
This pattern again supports the capacity of rAv17 to re-
duce proinflammatory responses after a lag phase. 
 rAv17 Enhances IL-10 mRNA Expression in Resting 
and Activated Microglia 
 Microglia were again stimulated with rAv17 (250 n M ) 
alone and together with LPS. rAv17 alone induced a strong 
and significant (p < 0.01) production of IL-10 mRNA at
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 Fig. 5.  a ,  b Time-dependent effects of rAv17 on LPS-induced 
COX-2 mRNA expression in cultivated microglia. Cells were stim-
ulated for 6 ( a ) and 24 h ( b ) with rAv17 (250 n M ), LPS (10 ng/ml) 
and simultaneously with rAv17 + LPS, respectively. The expres-
sion of mRNA was analyzed using TaqMan q-PCR and results for 
cells treated with rAv17 were compared to those stimulated solely 
with LPS. 18s RNA (a housekeeping gene) was used as the internal 
control. The data were assessed from at least 3 independent ex-
periments, each run in duplicate. Letters (a, b, c) indicate clusters 
of experimental groups which are significantly different from each 
other (p < 0.05; detailed p values are given in the text). All data are 
the mean ± SEM (95% CI values are given in the text). 
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2 h (101.6 ± 11.23%; 95% CI 53.33–149.9; p < 0.05), which 
decreased over time at 6 h (18.67 ± 4.63%; 95% CI –1.26 
to 38.59; p < 0.05) and 24 h (22.67 ± 6.33%; 95% CI –4.58 
to 49.92; not significant;  fig. 6 a–c). This suggests a short-
term induction of IL-10 production by rAv17 alone. LPS, 
on the other hand, induces a strong production of IL-10 
mRNA (100%) over the entire measurement period 
( fig. 6 a–c). Coexposure to rAv17 shows an increase of IL-
10 production at 2 h (trend: 160.9 ± 24.69%; 95% CI 54.68–
267.1; not significant) and no difference at 6 h (102.2 ± 
2.86%; 95% CI 89.9–114.5; not significant). Interestingly, 
a significant increase of the IL-10 mRNA level in costimu-
lated microglia could be detected at 24 h (135.0 ± 4.04%; 
95% CI 117.6–152.4; p < 0.05). These results indicate that 
rAv17 induces a brief response (2 h) in IL-10 mRNA pro-
duction in resting microglia. In LPS-stimulated cells, a 
short-term response could be seen after 2 h (trend); as for 
resting microglia over a longer period, an effect could be 
seen in IL-10 mRNA production after 24 h. 
 rAv17 Inhibits the Translocation of NF-κB in 
Microglia 
 The transcription factor NF-ĸB promotes the expres-
sion of inflammatory genes such as iNOS, COX-2, IL-1β, 
IL-6 and TNF-α after translocation from the cytosol into 
the nucleus  [22] . To study potential signaling pathways 
affected by rAv17, we investigated the effect of the para-
site protein on NF-ĸB activation. Therefore, transloca-
tion of NF-ĸB was visualized by immunocytochemical 
staining of its subunit p65 in cells exposed to rAv17 (250 
n M ) or LPS after 60 min. Resting microglia ( fig.  7 a) 
showed a comparable cytoplasmic staining (83.8 ± 9.66%; 
95% CI 59.0–109.0; p > 0.05) compared to LPS, but a dis-
tinctly reduced nuclear staining (14.5 ± 1.2%; 95% CI 
11.4–17.6; p < 0.001). This pattern was not appreciably 
altered by rAv17 alone ( fig. 7 c; rAv17 vs. control: nucleus, 
10.1 ± 1.18%; 95% CI 7.5–12.7; p > 0.05; cytosol, 82.1 ± 
7.61%; 95% CI 64.9–99.3; p > 0.05). In contrast, exposure 
to LPS led to a strong increase in nuclear staining ( fig. 7 b). 
On the contrary, cells simultaneously treated with LPS 
and rAv17 displayed an increase of cytoplasmic staining 
(166.0 ± 15.5%; 95% CI 132.0–200.1; p < 0.014) compared 
to LPS, but a reduced nuclear localization of the tran-
scription factor (LPS + rAv17 vs. LPS: 28.4 ± 1.81%; 95% 
CI 24.3–32.5; p < 0.001). Thus, rAv17 clearly interfered 
with the translocation of NF-ĸB ( fig. 7 d). These data show 
that rAv17 inhibits NF-ĸB translocation to the nucleus in 
microglia.
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 Fig. 6.  a–c rAv17 enhances IL-10 mRNA expression in resting and 
in activated microglia. Cells were stimulated for 2 ( a ), 6 ( b ) and
24 h ( c ) with rAv17 (250 n M ), LPS (10 ng/ml) and simultaneously 
with rAv17 + LPS, respectively. The expression of mRNA was an-
alyzed using TaqMan q-PCR and results for cells treated with 
rAv17 were compared to those stimulated solely with LPS. 18s 
RNA (a housekeeping gene) was used as the internal control. The 
data were assessed from at least 3 independent experiments, each 
run in duplicate. Letters (a, b, c) indicate clusters of experimental 
groups which are significantly different from each other (p < 0.05; 
detailed p values are given in the text). All data are the mean ± SEM 
(95% CI values are given in the text). 
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 rAv17 Inhibits the ERK Pathway in Microglia 
 The MAPK signaling pathway ERK1/2 was examined 
by Western blot analysis of the transient ERK-phosphor-
ylation (pERK1/2). MAPK signaling pathways are also in-
volved in the regulation of inflammatory responses  [23] . 
Stimulation with rAv17 (250 n M ) for 15 min did not sig-
nificantly differ the basic ERK phosphorylation (control: 
53.2 ± 5.33%; 95% CI 30.3–76.2; vs. rAv17: 47.2 ± 5.28%; 
95% CI 24.4–69.9; p > 0.05), whereas the addition of LPS 
strongly upregulated the amount of phosphorylated 
pERK1/2 (100%) in microglia. The simultaneous treat-
ment with rAv17 reduced activation of the ERK1/2 path-
way ( fig. 8 a, b) as could be concluded by the significantly 
(p < 0.01) decreased amount of pERK1/2 (82.5 ± 4.16%; 
95% CI 69.2–95.7; p < 0.05). Therefore, rAv17 also seems 
to interfere with the ERK signaling pathway.
 Discussion 
 This study showed that the parasite-derived immuno-
modulator rAv17 alters the LPS-induced proinflamma-
tory phenotype of rat microglia in vitro. Stimulation with 
LPS led to morphological changes, cytokine dysregulation 
(IL-1β, IL-6, TNF-α, IL-10) and the upregulation of cer-
tain enzymes (iNOS, COX-2), as well as a nuclear translo-
cation of NF-ĸB and phosphorylation of ERK in microg-
lia. After LPS stimulation, microglia displayed an amoe-
boid-like phenotype with large soma and a reduced 
number of pseudopodia. On the other hand, the untreated 
control group seemed to be more ramified. Costimulation 
of microglia with LPS and rAv17 led to a rather ramified 
morphology, giving the first evidence for a change in ac-
tivation state  [24] . To evaluate whether this change in 
phenotype leads to a transcriptional upregulation of in-
flammation-associated genes, qPCR measurements were 
carried out at different time points poststimulation (2, 6 
and 24 h). As proinflammatory markers, iNOS and the 
subsequent production of NO were analyzed. Addition-
ally, the proinflammatory cytokines IL-1β, IL-6, TNF-α 
and the PGE2-producing COX-2 were evaluated at the 
mRNA level. Moreover, TNF-α secretion was measured 
on the protein level using a specific ELISA. As an anti-
inflammatory cytokine, the IL-10 mRNA level was exert-
ed. Upon stimulation with LPS all inflammatory agents, 
including IL-10, were significantly upregulated at 6 and 
24 h. The upregulation of proinflammatory agents was 
significantly reduced at 24 h in LPS/rAv17 costimulated 
cells, but not at 6 h. The addition of rAv17 in a higher mo-
lecular dosage displayed comparable results as those seen 
for low-dose rAv17. This indicates that the lower concen-
tration (250 n M ) of rAv17 was already exerting the maxi-
mum effect. In contrast, rAv17 alone did not induce the 
transcription of any of these proinflammatory agents in 
a b
c d
Control
rAv17 LPS + rAv17
LPS
 Fig. 7.  a–d rAv17 inhibits nuclear translo-
cation of transcription factor NF-κB in mi-
croglia. Representative photomicrographs 
of in vitro-cultivated microglia.  a Resting 
microglia cells (control).  b LPS (10 ng/ml)-
stimulated microglia (positive control).
 c The addition of rAv17 (250 n M ) did not 
appreciably alter the NF-ĸB-appearance of 
resting microglia.  d rAv17 (250 n M ) inhib-
ited the LPS (10 ng/ml)-induced NF-ĸB 
translocation. Results for quantitative anal-
ysis are given in the text. Cells were culti-
vated upon cover glasses for 24 h and stim-
ulated with the indicated reagents for 60 
min. After fixation with Zamboni’s re-
agent, cells were stained with the primary 
antibody (NF-ĸB p65; Santa Cruz Biotech-
nology) and the NF-ĸB distribution was vi-
sualized with fluorescing anti-rabbit anti-
bodies (Alexa Fluor, Invitrogen) in fluores-
cence microscopy. Scale bar = 20 μm. 
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microglia at any time point. A different picture exists for 
IL-10. Here, a short time increase can be seen at 2 h for 
cells stimulated with rAv17 at a low dose. This upregula-
tion decreases over time until becoming insignificant at 
24 h. In LPS/rAv17 costimulated samples, an increase can 
be seen after 2 h (trend), which might be due to the short 
time effect seen for rAv17 stimulation alone. After 6 h no 
difference can be seen between LPS/rAv17 and LPS stim-
ulation. Interestingly, the IL-10 level was significantly 
higher at 24 h in costimulated LPS/rAv17 compared to 
LPS-stimulated cells. Thus, we might see two overlaying 
effects here. One short-term effect (2 h) where the appli-
cation of rAv17 leads to an LPS-independent increase in 
IL-10 mRNA, and one long-term effect (24 h) where it 
leads to an increase of IL-10 mRNA in LPS costimulated 
microglia. This long-term effect is accompanied by the 
reduction of proinflammatory agents. Thus, rAv17 induc-
es a clearly anti-inflammatory effect in this cell culture 
model of inflammation. Interestingly, another immuno-
modulator of  A. viteae , ES-62, shows similar delayed ef-
fects on proinflammatory mediators and interferes with 
the NF-ĸB and MAPK signaling pathway  [25] . 
 To date, little is known about the cellular mechanism 
that is mediated by rAv17. It has been shown, for exam-
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 Fig. 8.  a ,  b rAv17 inhibits the ERK-path-
way in microglia. Cells were stimulated for 
15 min with rAv17 (250 n M ), LPS (10 ng/
ml) and simultaneously with rAv17 + LPS, 
respectively. Activated ERK (pERK1/2) 
species were detected by Western blot anal-
ysis with antibodies specific for the 
pERK1/2. The amount of protein loaded
in each line was confirmed by measuring 
the amount of ERK1/2 using antibodies 
against the nonphosphorylated form of 
ERK (ERK2).  a Representative Western 
blot diagram.  b Blots were subjected to 
densitometry and results for cells treated 
with rAv17 were compared to those stimu-
lated solely with LPS (100%). The data were 
assessed from three independent experi-
ments. Letters (a, b, c) indicate clusters of 
experimental groups which are significant-
ly different from each other (p < 0.05; de-
tailed p values are given in the text). All 
data are the mean ± SEM (95% CI values 
are given in the text). 
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ple, that microglia express the IL-10 receptors  [26] and 
that IL-10 inhibits NF-ĸB-related pathways  [27] . Thus, 
the increase in IL-10 with the parallel reduction of IL-1β, 
IL-6, TNF-α, iNOS, NO and COX-2 might display a 
switch in the microglial phenotype from proinflamma-
tory to anti-inflammatory, as already described for mac-
rophages  [14] . The phenotypic plasticity observed in our 
study would be in line with the observations of Colton  [2] , 
who described three different activation states of microg-
lia in the brain and proposed that downregulation of the 
classical activation is mainly driven by feedback regula-
tion, with IL-10 being a key regulator. In our model there 
is a clear centralization of the NF-κB (p65) signal in LPS-
stimulated microglial cells. This centralization is not de-
tectable when cells are costimulated with rAv17. More-
over, a small yet significant reduction of pERK was seen 
in rAv17-treated microglial cells. This points towards an 
additional reduction in the MAP kinase-related signaling 
pathways. Taken together, we see a short time upregula-
tion of the IL-10 mRNA which is accompanied by an im-
paired NF-κB centralization and an inhibition of the 
MAP kinase signaling pathway. In the long term, we see 
a reduction of proinflammatory agents in LPS/rAv17 co-
stimulated cells compared to LPS stimulation only, which 
is accompanied by an increase in the IL-10 mRNA level. 
One potential explanation for these results might be a 
negative feedback mechanism by IL-10, which is regu-
lated by MAPK-like ERK1/2 and appears to be critical in 
the proinflammatory cytokine response to LPS  [28] . 
However, evidence for such wise regulation mainly comes 
from monocytes  [14, 29] . In addition, in the CNS, NF-κB 
activation can be negatively regulated by IL-10  [30] . Fur-
thermore, the inhibition of the ERK1/2 pathway is a cru-
cial mechanism in terms of alleviating neuroinflamma-
tion  [23] . Therefore, we propose an indirect mechanism 
via negative feedback inhibition that is mediated by IL-10 
as a possible explanation for the observed rAv17-mediat-
ed results in our study.
 The change in cytokine expression in our study might 
represent a switch from a proinflammatory to an anti-
inflammatory phenotype. As microglial cells are major 
sources of proinflammatory stimuli in neurodegenerative 
disease  [31] (e.g. Parkinson’s disease), a switch from a 
pro- to an anti-inflammatory phenotype is of high inter-
est. The eventual neuroprotective effects of these rAv17-
treated microglia need to be evaluated in future studies.
 Other studies corroborate the potential of a neuroim-
munomodulatory therapy in ND by parasite-derived 
products. The intraperitoneal administration of soluble 
helminth products induced a significant suppression of 
symptoms in experimental autoimmune encephalomy-
elitis, representing a valid murine model for multiple 
sclerosis  [32] . In addition, clinical trials with eggs from 
the nonpathogenic helminth  Trichuris suis have led to re-
duced numbers of gadolinium-enhancing MRI lesions in 
patients suffering from multiple sclerosis. Interestingly, 
this was accompanied by a downregulation of Th1-asso-
ciated cytokines and increased serum levels of IL-10  [33, 
34] . Components such as rAv17 are optimized during a 
longstanding host-parasite coevolution and might offer 
an efficient variant of anti-inflammatory therapy in ND.
 Conclusion 
 We demonstrated that rAv17 consequently reduced 
LPS-induced proinflammatory agents in a cell culture 
model of primary microglia. We assume that the major 
effect of rAv17 is exerted via the anti-inflammatory cyto-
kine IL-10 and, therefore, postulate that rAv17 triggers a 
switch, which results in an anti-inflammatory phenotype 
of microglia. We hope to confirm the proposed immuno-
modulatory mechanisms in a more physiological model 
(e.g. stimulation of microglia with neuromelanin) and to 
deepen insights into a potentially neuroprotective prop-
erty of rAv17. 
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